Under the terms of the announced transaction, shareholders are slated to receive $17.00 per share in cash. The agreement also includes a contingent value right, providing investors with 80% of net proceeds from the future monetization of the drug ampreloxetine over the next decade. However, legal representatives are raising concerns regarding restrictive clauses in the agreement that impose significant penalties on any competing bids, potentially chilling market interest and limiting the board's ability to secure a superior offer.

Ademi LLP is specifically examining whether the board of directors fulfilled its fiduciary duties during the negotiation process. The firm points to potential conflicts involving change-of-control arrangements that may grant substantial benefits to company insiders, raising questions about the fairness of the equity valuation and the transparency of the deal's approval process.